Implitapide

DB04852InvestigationalSmall molecule

Implitapide is a microsomal triglyceride transfer protein (MTP)-inhibitor.

Mechanism: MTP mediates triglyceride absorption and chylomicron secretion from the intestine and very-low-density lipoprotein (VLDL) secretion from the liver by linking lipid molecules with apolipoprotein B (apoB). Inhibition of MTP reduces the level of all apoB-containing lipoproteins, including LDL.
Curator reviewed
Primary indication: For the treatment of atherosclerosis.Curator reviewed
Formula / weight: C₃₅H₃₇N₃O₂ · 531.6872 g/mol (avg)
Code names: BAY-13-9952

Resolves to

Compound

Structure

InChIKeyAMNXBQPRODZJQR-DITALETJSA-NSMILESCC1=NC2=C(C3=CC=CC=C3N2CC2=CC(=CC=C2)[C@H](C2CCCC2)C(=O)N[C@@H](CO)C2=CC=CC=C2)C(C)=C1

Targets

What you can answer from here — as of August 26, 2024

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Implitapide, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.